Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
NASDAQ
Unprofitable
Unprofitable
-0.01 ( -0.25%)
Relative Strenght
16
Volume Buzz
76%
Earning Acce
No
Dist 52w H.
78%Quote Panel
Key Metrics
Relative Strength
FBRX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
-6659%2025-EPS
Analyst rating
No Data Available
Last analyst upgrade/downgrade
Rodman & Renshaw
initialisePrevious: Not converted
2024-06-18
Now: Buy
Brookline Capital
initialisePrevious: Not converted
2024-05-29
Now: Buy
Earnings Growth
YoY
Current
Estimates
Q3.22
N/A
-4.50
vs -13.50
Q4.22
N/A
-6.00
vs -5.25
Q1.23
N/A
-8.00
vs -4.25
Q2.23
N/A
-10.50
vs -5.25
Q3.23
N/A
-6.50
vs -4.50
Q4.23
N/A
-1.00
vs -6.00
Q1.24
N/A
-4.00
vs -8.00
Q2.24
N/A
-6.75
vs -10.50
Q3.24
N/A
-6.33
vs -6.50
Q4.24
N/A
-4.25
vs -1.00
Sales Growth
YoY
Current
Estimates
Q1.22
NA
NA vs NA
Q2.22
NA
NA vs NA
Q3.22
NA
NA vs NA
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
6K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Return on Equity
QoQ
Q3.22
-8%
-0.08
vs -0.08
Q4.22
-13%
-0.13
vs -0.08
Q1.23
-20%
-0.20
vs -0.13
Q2.23
-36%
-0.36
vs -0.20
Q3.23
-25%
-0.25
vs -0.36
Q4.23
-17%
-0.17
vs -0.25
Q1.24
-26%
-0.26
vs -0.17
Q2.24
-74%
-0.74
vs -0.26
Institutionnal Ownership
QoQ
Q3.22
26
26
vs 32
-19%
Q4.22
33
33
vs 26
27%
Q1.23
30
30
vs 33
-9%
Q2.23
31
31
vs 30
3%
Q3.23
32
32
vs 31
3%
Q4.23
35
35
vs 32
9%
Q1.24
32
32
vs 35
-9%
Q2.24
33
33
vs 32
3%
zacks.com
13 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
